MCRB
Seres Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MCRB
Seres Therapeutics, Inc.
A leading microbiome therapeutics company
101 Cambridgepark Drive, Cambridge, Massachusetts 02140
--
Seres Therapeutics, Inc., was incorporated in October 2010 under the laws of the State of Delaware. The Company is a commercial-stage microbiome therapy company focused on the development and commercialization of a new class of biopharmaceuticals designed to treat disease by modulating the microbiome and restore health by repairing the function of the disrupted microbiome to a non-disease state. The company is also designing microbiome therapies that are optimized to de-colonize pathogens and modulate host function to reduce and prevent infection and induce immune tolerance.
Earnings Call
Q1/2025
Estimate EPS1.97
Actual EPS3.76
Estimate Revenue10.00M
Actual Revenue--
Contradictions in Seres Therapeutics' 2025 Q1 Call: Phase 2 Study Design, Partnerships, and Strategic Implications
May 07,2025 07:26
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-2.61
Actual EPS-2.27
Estimate Revenue--
Actual Revenue--
Seres Therapeutics: Unpacking Strategic Contradictions in Partnerships and FDA Engagements
Aug 06,2025 09:54
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MCRB has released its 2025 Q3 earnings. EPS was reported at 0.94, versus the expected 1.28, missing expectations. The chart below visualizes how MCRB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MCRB has released its 2025 Q3 earnings report, with revenue of 351.00K, reflecting a YoY change of NaN%, and net profit of 8.20M, showing a YoY change of -90.76%. The Sankey diagram below clearly presents MCRB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
